ST Pharm에스티팜
237690 · KOSDAQ · ₩237690 · 에스티팜
₩72,500▼ ₩1,500 (2.03%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩332B | ₩274B | ₩285B | ₩249B | ₩166B |
| Cost of sales | ₩195B | ₩178B | ₩173B | ₩160B | ₩108B |
| Gross profit | ₩136B | ₩96B | ₩112B | ₩89B | ₩58B |
| Operating income | ₩55B | ₩28B | ₩34B | ₩18B | ₩5.6B |
| Net income | ₩55B | ₩32B | ₩18B | ₩18B | ₩3.4B |
| Net income to shareholders | ₩55B | ₩35B | ₩20B | ₩18B | ₩3.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩783B | ₩722B | ₩675B | ₩579B | ₩499B |
| Current assets | ₩373B | ₩330B | ₩348B | ₩271B | ₩244B |
| Cash and equivalents | ₩31B | ₩63B | ₩50B | ₩50B | ₩39B |
| Total liabilities | ₩190B | ₩219B | ₩289B | ₩230B | ₩173B |
| Current liabilities | ₩165B | ₩133B | ₩84B | ₩179B | ₩75B |
| Borrowings | ₩77B | ₩115B | ₩189B | ₩45B | ₩106B |
| Total equity | ₩593B | ₩503B | ₩387B | ₩341B | ₩326B |
| Shareholders' equity | ₩593B | ₩503B | ₩385B | ₩338B | ₩323B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩14B | ₩109B | ₩1.3B | ₩7B | ₩7.3B |
| Capital spending | ₩47B | ₩83B | ₩43B | ₩60B | ₩52B |
| Free cash flow | −₩33B | ₩27B | −₩42B | −₩53B | −₩45B |
| Dividends paid | ₩10B | ₩9.4B | ₩9.4B | ₩9.4B | ₩0 |
Consolidated where available. Amounts in won.
Also known as: ST Pharm / 에스티팜 / 237690 / KRX:237690
Source: KRX statistical information